Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta
| Author | Sh Salehpour | en |
| Author | S Tavakkoli | en |
| Issued Date | 2008-01-31 | en |
| Abstract | he main objective of this study was to determine the efficacy and safety of pamidronate in improving bone mineralization and reducing fracture incidence in osteogenesis imperfecta (OI). Materials and Methods: Intravenous pamidro-nate was administered to 64 children, aged 18 months to 10 years old, with severe OI, in a 1 mg/kg single daily dose for 3 sequentional days at 4 month intervals, for over a period of 24-48 months. Clinical status, biochemical characteris-tics including bone turnover markers, the bone mineral density of the lumbar spine and femoral neck, and radiologic changes were assessed regularly during treatment. Results: The number of fractures decreased from median of 8 (range 4-11) to 0 fractures/year (range 0-4) (P | en |
| DOI | https://doi.org/ | en |
| Keyword | Osteogenesis imperfecta | en |
| Keyword | Pamidronate | en |
| Publisher | Brieflands | en |
| Title | Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 77494-pdf.pdf
- Size:
- 249.63 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF